日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab

在一项长期的 3 期 galcanezumab 研究中,慢性偏头痛转变为发作性偏头痛。

Diener, Hans-Christoph; Day, Kathleen A; Lipsius, Sarah; Aurora, Sheena K; Hindiyeh, Nada A; Detke, Holland C

Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report

解决阿尔茨海默病治疗试验中多样性严重不足的问题:CTAD工作组报告

Raman, R; Aisen, P S; Carillo, M C; Detke, M; Grill, J D; Okonkwo, O C; Rivera-Mindt, M; Sabbagh, M; Vellas, B; Weiner, M; Sperling, R

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

Galcanezumab 用于既往多种偏头痛预防药物治疗失败的患者:CONQUER 试验开放标签期的结果

Reuter, Uwe; Lucas, Christian; Dolezil, David; Hand, Austin L; Port, Martha D; Nichols, Russell M; Stroud, Chad; Tockhorn-Heidenreich, Antje; Detke, Holland C

Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)

患者功能和残疾的变化:一项评估 galcanezumab 用于预防慢性偏头痛的 3 期双盲、随机、安慰剂对照临床试验 (REGAIN) 的结果

Ford, Janet; Tassorelli, Cristina; Leroux, Elizabeth; Wang, Shufang; Ayer, David; Nichols, Russell; Detke, Holland

Feature selection for proximity estimation in COVID-19 contact tracing apps based on Bluetooth Low Energy (BLE)

基于低功耗蓝牙(BLE)的COVID-19接触者追踪应用程序中近距离估计的特征选择

Madoery, Pablo G; Detke, Ramiro; Blanco, Lucas; Comerci, Sandro; Fraire, Juan; Gonzalez Montoro, Aldana; Bellassai, Juan Carlos; Britos, Grisel; Ojeda, Silvia; Finochietto, Jorge M

Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report

阿尔茨海默病疾病修饰的非淀粉样蛋白疗法:欧盟/美国CTAD工作组报告

Gauthier, Serge; Aisen, P S; Cummings, J; Detke, M J; Longo, F M; Raman, R; Sabbagh, M; Schneider, L; Tanzi, R; Tariot, P; Weiner, M; Touchon, J; Vellas, B

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

Galcanezumab治疗慢性偏头痛:一项随机、双盲、安慰剂对照的REGAIN研究

Detke, Holland C; Goadsby, Peter J; Wang, Shufang; Friedman, Deborah I; Selzler, Katherine J; Aurora, Sheena K

Measures of outcome for stimulant trials: ACTTION recommendations and research agenda

兴奋剂试验结果的衡量指标:行动建议和研究议程

Kiluk, Brian D; Carroll, Kathleen M; Duhig, Amy; Falk, Daniel E; Kampman, Kyle; Lai, Shengan; Litten, Raye Z; McCann, David J; Montoya, Ivan D; Preston, Kenzie L; Skolnick, Phil; Weisner, Constance; Woody, George; Chandler, Redonna; Detke, Michael J; Dunn, Kelly; Dworkin, Robert H; Fertig, Joanne; Gewandter, Jennifer; Moeller, F Gerard; Ramey, Tatiana; Ryan, Megan; Silverman, Kenneth; Strain, Eric C

Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice

奥氮平长效注射剂:常规临床实践中注射后谵妄/镇静综合征的初步经验回顾

Bushe, Chris J; Falk, Deborah; Anand, Ernie; Casillas, Marta; Perrin, Elena; Chhabra-Khanna, Rashna; Detke, Holland C

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study

接受奥氮平长效注射治疗的精神分裂症患者的基线特征和住院情况:一项非干预性、前瞻性观察性安全性研究的中期分析

Jones, Meghan E; Andrews, Jeffrey S; Faries, Douglas E; Landry, John; Xu, Jenny; Detke, Holland C; Chhabra-Khanna, Rashna; McDonnell, David P